# Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)

> **NCT02231177** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 47 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** BI 1744 CL
- **DRUG:** BI 1744 CL/Tiotropium FDC
- **DRUG:** Tiotropium

## Key facts

- **NCT ID:** NCT02231177
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2008-11
- **Final completion:** —
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2016-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02231177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02231177, "Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02231177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*